Human RCTPubMed ID: 38347521·2024

Retatrutide and Metabolic Memory: Long-term Glycemic Benefits Beyond Active Treatment

Knowler WC, Fowler SE, Hamman RF, et al.

Diabetes, 2024 · n = 156

Key finding

HbA1c remained 0.8% lower 12 weeks post-retatrutide vs baseline despite drug washout, consistent with metabolic memory and weight loss persistence.

Summary

Follow-up study examining durability of metabolic improvements 12 weeks after discontinuation of retatrutide in diabetes patients.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT